Securities Code: 002393 Securities Abbreviation: Lisheng Pharmaceutical Announcement No.: 2026-026
Tianjin Lisheng Pharmaceutical Co., Ltd. Announcement on the Progress of Using Idle Raised Funds for Cash Management
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions.
Tianjin Lisheng Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the fourth meeting of the Eighth Board of Directors on March 24, 2026, and the 2025 Annual Shareholders' Meeting on April 15, 2026. The proposal "On the Quota for the Company to Use Idle Raised Funds for Cash Management in 2026" was deliberated and approved. The Company is permitted to use idle raised funds not exceeding RMB 874 million and subsequent interest and income to purchase principal-protected investment products with high security and good liquidity. The term of these products shall not exceed 12 months from the date approved by the Shareholders' Meeting, and the funds can be rolled over within the approved quota and period. Regarding the above matters, the Company's sponsor institution issued a clear opinion of consent. For details, please refer to the "Announcement on the Quota for the Company to Use Idle Raised Funds for Cash Management in 2026" (Announcement No.: 2026-020) disclosed by the Company on Juchao Information Network (www.cninfo.com.cn) on March 25, 2026, and the "Verification Opinion of Bohai Securities on Tianjin Lisheng Pharmaceutical Co., Ltd.'s Use of Idle Raised Funds for Cash Management."